Assessing Gingivitis of 3 Different Dentifrices Compared to a Negative Control.

NCT ID: NCT06892834

Last Updated: 2025-07-02

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE2

Total Enrollment

120 participants

Study Classification

INTERVENTIONAL

Study Start Date

2025-03-25

Study Completion Date

2025-06-19

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The primary objective of this study is to evaluate the effect of two experimental hops extract-containing dentifrices on gingivitis relative to a positive control 0.454% SnF2 dentifrice and a negative control dentifrice after 12 weeks of product use.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Gingivitis

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

DOUBLE

Participants Investigators

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Positive Control

0.454% stannous fluoride, 0.533% zinc citrate

Group Type ACTIVE_COMPARATOR

Stannous Fluoride Dentifrice

Intervention Type DRUG

Each subject will be randomly assigned to one of four treatment products and will be asked to brush 2x a day (1 minute per brushing) for 3 months.

Experimental #1

0.243% NaF with 0.1% Hops, Humulus lupulus extract \[0.045% hops β-acids\]

Group Type EXPERIMENTAL

Sodium Fluoride Dentifrice

Intervention Type DRUG

Each subject will be randomly assigned to one of four treatment products and will be asked to brush 2x a day (1 minute per brushing) for 3 months.

Experimental #2

0.243% NaF with 0.5% Hops, Humulus lupulus extract \[0.225% hops β-acids\]

Group Type EXPERIMENTAL

Sodium Fluoride Dentifrice

Intervention Type DRUG

Each subject will be randomly assigned to one of four treatment products and will be asked to brush 2x a day (1 minute per brushing) for 3 months.

Negative Control

0.76% Sodium Monofluorophosphate

Group Type ACTIVE_COMPARATOR

Sodium monofluorophosphate dentifrice

Intervention Type DRUG

Each subject will be randomly assigned to one of four treatment products and will be asked to brush 2x a day (1 minute per brushing) for 3 months.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Stannous Fluoride Dentifrice

Each subject will be randomly assigned to one of four treatment products and will be asked to brush 2x a day (1 minute per brushing) for 3 months.

Intervention Type DRUG

Sodium Fluoride Dentifrice

Each subject will be randomly assigned to one of four treatment products and will be asked to brush 2x a day (1 minute per brushing) for 3 months.

Intervention Type DRUG

Sodium monofluorophosphate dentifrice

Each subject will be randomly assigned to one of four treatment products and will be asked to brush 2x a day (1 minute per brushing) for 3 months.

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Be at least 18 years of age;
* Provide written informed consent prior to participation and be given a signed copy of the informed consent form;
* Be in general good health as determined by the Investigator based on a review of the health history/update for participation in the trial; If female of child-bearing potential, agree to use a medically approved method of birth control for the duration of the study. Acceptable methods of medically approved birth control include: at least 3 months of use of a hormonal birth control (including oral contraceptives, hormone birth control patch, vaginal contraceptive ring, injectable contraceptives, or hormone implant), double-barrier method, intrauterine devices, non-heterosexual lifestyle or agrees to use contraception if planning on changing to heterosexual partner(s), vasectomy of partner at least 6 months prior to screening. Not applicable to females not of child-bearing potential (females who have undergone a sterilization procedure including hysterectomy, bilateral oophorectomy, bilateral tubal ligation, complete endometrial ablation) or have been post-menopausal for at least 1 year prior;
* If female and of child-bearing potential, agree to immediately inform the study investigator if they become pregnant;
* Have at least 20 gradable teeth;
* Have mild to moderate gingivitis with a range of 10 to 70% bleeding sites;
* Agree to return for scheduled visits and follow the study procedures;
* Agree to refrain from use of any non-study oral hygiene products for the duration of the study; regular floss users can continue to floss in their customary manner.
* Agree to delay any elective dentistry, including dental prophylaxis, until the completion of the study; and
* Agree to refrain from any oral hygiene the morning of each visit.

Exclusion Criteria

* Having taken antibiotic, anti-inflammatory, or anticoagulant medications within 4 weeks of the baseline visit;
* Having any oral conditions that could interfere with study compliance and/or examination procedures, such as widespread caries, soft or hard tissue tumor of the oral cavity, severe gingivitis, or advanced periodontal disease;
* Females of child-bearing potential who are not using a medically approved method of birth control (i.e., hormonal contraceptives including oral contraceptives, hormone birth control patch, vaginal contraceptive ring, injectable contraceptives, or hormone implant, double-barrier method, intrauterine devices, non-heterosexual lifestyle or agrees to use contraception if planning on changing to heterosexual partner(s), vasectomy of partner at least 6 months prior to screening) or who have not been using hormonal birth control for a minimum of 3 months prior to study enrollment;
* Taking medication that alters gingival appearance or gingival bleeding (e.g., calcium channel blockers, anticonvulsants, or immunosuppressants) within one month prior to study initiation;
* Regularly (\>5x/week) using anti-gingivitis treatments (e.g., stannous fluoride toothpaste, or anti-gingivitis mouthwashes, such as those containing chlorohexidine) in the month prior to screening;
* Removable oral appliances;
* Fixed facial or lingual orthodontic appliances;
* Have a positive pregnancy test (Clearblue) at baseline or self-reported pregnancy during the study; ;
* Any diseases or condition that might interfere with the safe participation in the study according to the study investigator;
* Inability to undergo study procedures; and
* Allergic reactions to any of the study toothpastes and/or ingredients in the study toothpastes.
Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Procter and Gamble

INDUSTRY

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

All Sum Research

Role: PRINCIPAL_INVESTIGATOR

All Sum Research

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

All Sum ResearchAll Sum Research Center Ltd.

Mississauga, Ontario, Canada

Site Status

Countries

Review the countries where the study has at least one active or historical site.

Canada

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

2024026

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

A Bleeding-Model Clinical Study
NCT05916508 COMPLETED NA
Compare Anti-inflammatory Dentifrices
NCT00762528 COMPLETED PHASE4